WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ Water Vapor Therapy (WVTT) for benign prostatic hyperplasia (BPH). The findings, presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, reveal significant differences in patient outcomes favoring the UroLift™ System, particularly in early recovery, sexual function, and overall satisfaction.
CLEAR assessed treatment outcomes for 79 BPH patients, evaluating catheter independence, patient satisfaction, sexual function, and procedural impact on daily activities. The study’s findings indicate that the UroLift™ System provides a quicker recovery, less postoperative discomfort, and better preservation of sexual function compared to Rezūm.
Key results include:
- Catheter Independence: Only one out of 42 UroLift™ System patients failed to achieve catheter independence within three to seven days post-procedure, compared to 10 of 37 patients treated with Rezūm.
- Reduced Discomfort: Rezūm patients reported more pain during urination and noticed blood in their urine more frequently, with these issues persisting for up to a month post-treatment.
- Improved Sexual Function: UroLift™ patients showed superior scores in erectile and orgasmic function one month after the procedure, along with better ejaculatory function and overall sexual satisfaction at three months.
- Higher Patient Satisfaction: UroLift™ consistently ranked higher in composite satisfaction, which included ratings on procedural experience, symptom relief, and willingness to recommend the treatment.
“Comparative clinical trials play a crucial role in guiding treatment decisions for benign prostatic hyperplasia by providing clear, evidence-based insights into safety, efficacy, and patient experience,” said Dr. Matt Ashley, Associate Medical Director at Teleflex. “Understanding how these therapies perform not only in clinical settings but also in real-world patient recovery is essential. At Teleflex, we are committed to advancing research that supports the UroLift™ procedure as a trusted, patient-preferred option for BPH symptom treatment.”
Lead investigator Mr. Mark Rochester, Consultant Urologist at Norfolk and Norwich University Hospital, emphasized the practical significance of the findings. “These results provide important insights into the real-world recovery experience of BPH patients undergoing minimally invasive treatments. The differences in patient experience between UroLift™ System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path.”
The CLEAR study underscores the UroLift™ System’s potential to offer an improved treatment experience for BPH patients, combining enhanced recovery with greater long-term satisfaction.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.